These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 16724954)

  • 21. TSAO derivatives the first non-peptide inhibitors of HIV-1 RT dimerization.
    Camarasa MJ; Velázquez S; San-Félix A; Pérez-Pérez MJ
    Antivir Chem Chemother; 2005; 16(3):147-53. PubMed ID: 16004078
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonnucleoside inhibitor binding affects the interactions of the fingers subdomain of human immunodeficiency virus type 1 reverse transcriptase with DNA.
    Peletskaya EN; Kogon AA; Tuske S; Arnold E; Hughes SH
    J Virol; 2004 Apr; 78(7):3387-97. PubMed ID: 15016861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new potent HIV-1 reverse transcriptase inhibitor. A synthetic peptide derived from the interface subunit domains.
    Morris MC; Robert-Hebmann V; Chaloin L; Mery J; Heitz F; Devaux C; Goody RS; Divita G
    J Biol Chem; 1999 Aug; 274(35):24941-6. PubMed ID: 10455170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Designing anti-AIDS drugs targeting the major mechanism of HIV-1 RT resistance to nucleoside analog drugs.
    Sarafianos SG; Hughes SH; Arnold E
    Int J Biochem Cell Biol; 2004 Sep; 36(9):1706-15. PubMed ID: 15183339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitors.
    Santos LH; Ferreira RS; Caffarena ER
    Mem Inst Oswaldo Cruz; 2015 Nov; 110(7):847-64. PubMed ID: 26560977
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy.
    Balzarini J
    Biochem Pharmacol; 1999 Jul; 58(1):1-27. PubMed ID: 10403515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cross-resistance analysis and molecular modeling of nonnucleoside reverse transcriptase inhibitors targeting drug-resistance mutations in the reverse transcriptase of human immunodeficiency virus.
    Yang SS; Pattabiraman N; Gussio R; Pallansch L; Buckheit RW; Bader JP
    Leukemia; 1997 Apr; 11 Suppl 3():89-92. PubMed ID: 9209308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity.
    Yang SS; Fliakas-Boltz V; Bader JP; Buckheit RW
    Leukemia; 1995 Oct; 9 Suppl 1():S75-85. PubMed ID: 7475321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dimerization inhibitors of HIV-1 reverse transcriptase, protease and integrase: a single mode of inhibition for the three HIV enzymes?
    Camarasa MJ; Velázquez S; San-Félix A; Pérez-Pérez MJ; Gago F
    Antiviral Res; 2006 Sep; 71(2-3):260-7. PubMed ID: 16872687
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NMR characterization of HIV-1 reverse transcriptase binding to various non-nucleoside reverse transcriptase inhibitors with different activities.
    Thammaporn R; Yagi-Utsumi M; Yamaguchi T; Boonsri P; Saparpakorn P; Choowongkomon K; Techasakul S; Kato K; Hannongbua S
    Sci Rep; 2015 Oct; 5():15806. PubMed ID: 26510386
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of human immunodeficiency virus type-1 reverse transcriptase by a novel peptide derived from the viral integrase.
    Oz Gleenberg I; Herschhorn A; Goldgur Y; Hizi A
    Arch Biochem Biophys; 2007 Feb; 458(2):202-12. PubMed ID: 17257575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097.
    Das K; Sarafianos SG; Clark AD; Boyer PL; Hughes SH; Arnold E
    J Mol Biol; 2007 Jan; 365(1):77-89. PubMed ID: 17056061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-based design of conformationally flexible reverse transcriptase inhibitors to combat resistant HIV.
    Hao GF; Yang SG; Yang GF
    Curr Pharm Des; 2014; 20(5):725-39. PubMed ID: 23688080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An Alternative HIV-1 Non-Nucleoside Reverse Transcriptase Inhibition Mechanism: Targeting the p51 Subunit.
    Chan KF; Su CT; Krah A; Phua SX; Yeo JY; Ling WL; Bond PJ; Gan SK
    Molecules; 2020 Dec; 25(24):. PubMed ID: 33322154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV-reverse transcriptase inhibition: inclusion of ligand-induced fit by cross-docking studies.
    Ragno R; Frasca S; Manetti F; Brizzi A; Massa S
    J Med Chem; 2005 Jan; 48(1):200-12. PubMed ID: 15634014
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advances in rationally designed dual inhibitors of HIV-1 reverse transcriptase and integrase.
    Gu SX; Xue P; Ju XL; Zhu YY
    Bioorg Med Chem; 2016 Nov; 24(21):5007-5016. PubMed ID: 27658796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Virtual screening, identification, and biochemical characterization of novel inhibitors of the reverse transcriptase of human immunodeficiency virus type-1.
    Herschhorn A; Hizi A
    J Med Chem; 2008 Sep; 51(18):5702-13. PubMed ID: 18800765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase.
    Menéndez-Arias L
    Virus Res; 2008 Jun; 134(1-2):124-46. PubMed ID: 18272247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutations that abrogate human immunodeficiency virus type 1 reverse transcriptase dimerization affect maturation of the reverse transcriptase heterodimer.
    Wapling J; Moore KL; Sonza S; Mak J; Tachedjian G
    J Virol; 2005 Aug; 79(16):10247-57. PubMed ID: 16051818
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Developing novel nonnucleoside HIV-1 reverse transcriptase inhibitors: beyond the butterfly.
    Basavapathruni A; Anderson KS
    Curr Pharm Des; 2006; 12(15):1857-65. PubMed ID: 16724952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.